News | January 29, 2026
Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Subscribe To Our Newsletter & Stay Updated
